Itsuro Nagase
Senior Vice President, Head of Primary Focus Lead - Targeted Protein Degradation Astellas Pharma
Seminars
Tuesday 27th October 2026
Clinical Proof of Concept of Setidegrasib (ASP3082)
2:00 pm
- Astellas’ strategy to strengthen its R&D pipeline and deliver meaningful value to patients
- Clinical proof of concept of Setidegrasib in advanced non small cell lung cancer and pancreatic cancer
- Beyond Setidegrasib: defining the next steps for targeted protein degradation
